{
    "2019-10-24": [
        [
            {
                "time": "",
                "original_text": "贝达药业：前三季度净利1.99亿元 同比增34%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "净利",
                        "同比增",
                        "前三季"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)第三季度扣非净利润升60.88%至1.06亿元",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "扣非净利润",
                        "升",
                        "第三季度"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：前三季度净利润同比增34.37%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "净利润",
                        "同比增",
                        "前三季度"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【民生医药】医药生物2019年三季报总结：基本面进入值得期待的新周期",
                "features": {
                    "keywords": [
                        "民生医药",
                        "医药生物",
                        "三季报",
                        "基本面",
                        "新周期"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}